ID | 1363 |
Name of the vaccine | CombAct-HIB |
Microbe | Bacteria |
Disease name | Haemophilus influenzae type b (Hib) |
Name of bacteria | Haemophilus influenzae |
Type of vaccine | Combination |
Nucleic acid content | DNA |
Age | up to 3 days |
Description of the vaccine | DTwP used to reconstitute freeze-dried Hib vaccine. |
Name of the manufacturer | Sanofi Pasteur, a Sanofi Company |
Name of the manufacturing country | South Africa |
Year of manufacture | 2009 |
Clinical Phase status | Clinical - Phase 3 |
Bacterial strain | Anaerobic gram-negative coccobacillus. |
Efficacy | NA
|
Vaccine formulation | Liquid suspension |
Dosage | Primary series of 3 doses and booster dose at 15 to 18 months. |
Mechanism of action | NA |
Route of administration | Intramuscular |
Indications | NA |
Export | NA |
Approval | NA |
Adjuvant | NA |
Repurposing | For diphtheria, pertussis, polio, hepatitis B and Hib. |
Side effects of vaccine | NA |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | 31444785 |
Clinical trial number | NCT00362336 |
Reference | https://www.tabletwise.net/southafrica/combact-hib-vaccine |
Other name | NA |
Additional Links | NA
|